MLchartDataset catalogue

VEGFR/PDGFR dual kinase inhibitor TAK-593

Term · Oncology and biomedicine · MLC-T-ONC-017482

An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.

Table 1. Record
IdentifierMLC-T-ONC-017482
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-017482",
  "term": "VEGFR/PDGFR dual kinase inhibitor TAK-593",
  "field": "Oncology and biomedicine",
  "definition": "An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vegfr-pdgfr-dual-kinase-inhibitor-tak-593/"
}

Record 17,171 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.